FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Research output: Contribution to journalArticle

Abstract

Patients with acute myeloid leukemia who harbor an FMS-like tyrosine kinase 3 (FLT3) mutation present several dilemmas for the clinician. The results of an FLT3 mutation test, which can be influenced by several variables, need to be interpreted according to the clinical setting and there is a need for internationally standardized FLT3 mutation assays. Because of the lack of prospective studies, the role of allogeneic transplantation as consolidation therapy is still somewhat controversial, but the preponderance of evidence suggests that transplantation in first remission, if possible, is probably the best option. Clinically useful FLT3 inhibitors are hopefully on the near horizon and are being studied in the context of current treatment paradigms.

Fingerprint

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Mutation
Homologous Transplantation
Transplantation
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{12aa4a05f12a4d6f9acc60369680879a,
title = "FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?",
abstract = "Patients with acute myeloid leukemia who harbor an FMS-like tyrosine kinase 3 (FLT3) mutation present several dilemmas for the clinician. The results of an FLT3 mutation test, which can be influenced by several variables, need to be interpreted according to the clinical setting and there is a need for internationally standardized FLT3 mutation assays. Because of the lack of prospective studies, the role of allogeneic transplantation as consolidation therapy is still somewhat controversial, but the preponderance of evidence suggests that transplantation in first remission, if possible, is probably the best option. Clinically useful FLT3 inhibitors are hopefully on the near horizon and are being studied in the context of current treatment paradigms.",
author = "Levis, {Mark J}",
year = "2013",
doi = "10.1182/asheducation-2013.1.220",
language = "English (US)",
volume = "2013",
pages = "220--226",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - FLT3 mutations in acute myeloid leukemia

T2 - what is the best approach in 2013?

AU - Levis, Mark J

PY - 2013

Y1 - 2013

N2 - Patients with acute myeloid leukemia who harbor an FMS-like tyrosine kinase 3 (FLT3) mutation present several dilemmas for the clinician. The results of an FLT3 mutation test, which can be influenced by several variables, need to be interpreted according to the clinical setting and there is a need for internationally standardized FLT3 mutation assays. Because of the lack of prospective studies, the role of allogeneic transplantation as consolidation therapy is still somewhat controversial, but the preponderance of evidence suggests that transplantation in first remission, if possible, is probably the best option. Clinically useful FLT3 inhibitors are hopefully on the near horizon and are being studied in the context of current treatment paradigms.

AB - Patients with acute myeloid leukemia who harbor an FMS-like tyrosine kinase 3 (FLT3) mutation present several dilemmas for the clinician. The results of an FLT3 mutation test, which can be influenced by several variables, need to be interpreted according to the clinical setting and there is a need for internationally standardized FLT3 mutation assays. Because of the lack of prospective studies, the role of allogeneic transplantation as consolidation therapy is still somewhat controversial, but the preponderance of evidence suggests that transplantation in first remission, if possible, is probably the best option. Clinically useful FLT3 inhibitors are hopefully on the near horizon and are being studied in the context of current treatment paradigms.

UR - http://www.scopus.com/inward/record.url?scp=84899491662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899491662&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2013.1.220

DO - 10.1182/asheducation-2013.1.220

M3 - Article

C2 - 24319184

AN - SCOPUS:84899491662

VL - 2013

SP - 220

EP - 226

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

ER -